Gene polymorphism of HCV is an important cause of drug resistance to direct-acting antivirals (DAAs).
Methods
Nested PCR assays were performed to amplify the HCV viral regions of NS3, NS5A and NS5B.
Results
Major resistant mutation A156S was found in 18.33% of patients with HCV-1b and 64.28% of patients with HCV-2a. HCV-6a patients had a Q80K mutation rate of 95.45%, while the mutation rate of V170I was up to 100%. Mutation frequency varied with the different genotypes of HCV. The proportion of four resistance mutations (M36L, Q80K, A156S, V170I) in different groups were statistically significant (P≤0.05). Resistant mutation Q30R was detected in 116 (72.5%) samples with HCV-1b and -6a, L31M was found in 16 patients, including 12 with HCV-2a and 4 with HCV-6a, H58P was discovered in 42.5% (68/160) of patients with the genotypes Q30R, L31M and H58P; Y93C was found in 9individuals with only HCV-2a. In HCV NS5B sequences, only a few resistant variants were detected, including C316N and S282T.
Conclusions
Naturally occurring dominant resistance mutations to HCV DAAs pre-existed in treatment-naive patients in China. Mutation frequency and characteristics varied with the HCV genotype.
References
1.
LalezariJ., BoxT., O'RiordanW.IDX184 in combination with pegylated interferon-alpha2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.Antivir Ther2013; 18: 755–764.
2.
LauerG.M., WalkerB.D.Hepatitis C virus infection.N Engl J Med2001; 345: 41–52.
3.
HadziyannisS.J., SetteH.J., MorganT.R.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.Ann Intern Med2004; 140: 346–355.
4.
HézodeC., ForestierN., DusheikoG.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.N Engl J Med2009; 360: 1839–1850.
5.
GuedjJ., PangP.S., DenningJ.Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofobuvir (GS-7977) and GS-0938.Antivir Ther2014; 19: 211–220.
6.
SarrazinC., KiefferT.L., BartelsD.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.Gastroenterology2007; 132: 1767–1777.
7.
FrancoS., PareraM., AparicioE.Genetic and catalytic efficiency structure of an HCV protease quasispecies.Hepatology2007; 45: 899–910.
8.
KuntzenT., TimmJ., BericalA.Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients.Hepatology2008; 48: 1769–1778.
9.
SarrazinC., RouzierR., WagnerF.SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.Gastroenterology2007; 132: 1270–1278.
10.
BartelsD.J., ZhouY., ZhangE.Z.Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.J Infect Dis2008; 198: 800–807.
11.
VicentiI., RosiA., SaladiniF.Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.J Antimicrob Chemother2012; 67: 984–987.
12.
FridellR.A., WangC., SunJ.H.Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.Hepatology2011; 54: 1924–1935.
13.
GaudieriS., RauchA., PfafferottK.Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.Hepatology2009; 49: 1069–1082.
14.
SunS.C., BaeA., QiX.Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naive HCV patient isolates.J Viral Hepat2011; 18: 861–870.
15.
ArnaudC., PradatP., SpazianteM.Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-EIE2 antibodies compared to IP-10 and IL28B genotypes.Antivir Ther2013; 18: 1027–1032.
16.
CaiQ., ZhaoZ., LiuY.Comparison of three different HCV genotyping methods: core, NS5B sequence analysis and line probe assay.Int J Mol Med2013; 31: 347–352.
17.
TaylorM.W., TsukaharaT., BrodskyL.Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.J Virol2007; 81: 3391–3401.
18.
ValletS., VironF., HenquellC.NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1–5.Antivir Ther2011; 16: 1093–1102.
19.
PaolucciS., FiorinaL., PirallaA.Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients.Virol J2012; 9: 245.
20.
HernandezD., ZhouN., UelandJ.Natural prevalence of NSSA polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NSSA inhibitor.J Clin Virol2013; 57: 13–18.
21.
RobertsS.K., CooksleyG., DoreG.J.Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.Hepatology2008; 48: 398–406.
22.
MaimoneS., MusolinoC., SquadritoG.NS3 genetic variability in HCV genotype-1b isolates from liver specimens and blood samples of treatment-native patients with chronic hepatitis C.Antivir Ther2013; 18: 131–134.
23.
KuntzenT., TimmJ., BericalA.Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients.Hepatology2008; 48: 1769–1778.
24.
LampeE., Lewis-XimenezL., Espirito-SantoM.P.Genetic diversity of HCV in Brazil.Antivir Ther2013; 18: 435–444.
